QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 piper-sandler-maintains-overweight-on-nurix-therapeutics-lowers-price-target-to-32

Piper Sandler analyst Joseph Catanzaro maintains Nurix Therapeutics (NASDAQ:NRIX) with a Overweight and lowers the price tar...

 oppenheimer-maintains-outperform-on-nurix-therapeutics-lowers-price-target-to-28

Oppenheimer analyst Matthew Biegler maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and lowers the price target...

 levi-strauss-usana-health-sciences-and-3-stocks-to-watch-heading-into-friday

US stock futures up, Apogee Enterprises, Levi Strauss, VolitionRX, USANA Health Sciences, Nurix Therapeutics report results.

 nurix-and-gilead-advance-irak4-degrader-gs-6791-into-clinical-trials-after-preclinical-results-in-skin-disease

Nurix Therapeutics, Inc. (NASDAQ:NRIX) today announced the presentation of preclinical data from GS-6791/NX-0479, a novel IRAK4...

 morgan-stanley-maintains-equal-weight-on-nurix-therapeutics-lowers-price-target-to-16

Morgan Stanley analyst Terence Flynn maintains Nurix Therapeutics (NASDAQ:NRIX) with a Equal-Weight and lowers the price tar...

 hc-wainwright--co-maintains-buy-on-nurix-therapeutics-lowers-price-target-to-34

HC Wainwright & Co. analyst Robert Burns maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and lowers the price targ...

 ubs-maintains-buy-on-nurix-therapeutics-lowers-price-target-to-26

UBS analyst David Dai maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and lowers the price target from $30 to $26.

 oppenheimer-maintains-outperform-on-nurix-therapeutics-lowers-price-target-to-30

Oppenheimer analyst Matthew Biegler maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and lowers the price target...

 stephens--co-reiterates-overweight-on-nurix-therapeutics-maintains-30-price-target

Stephens & Co. analyst Sudan Loganathan reiterates Nurix Therapeutics (NASDAQ:NRIX) with a Overweight and maintains $30 ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION